Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosalt Regulatory News (SALT)

Share Price Information for Microsalt (SALT)

Share Price is delayed by 15 minutes
Get Live Data
35.50    0.00 (0.00%)
Bid:
32.00
Ask:
39.00
Spread: 7.00 (21.875%)
Market Cap: £20.49m
SALT Live PriceLast checked at - London Stock Exchange

Intraday Microsalt Share Chart

Trading Update

14 Nov 2025 07:00

RNS Number : 5214H
MicroSalt PLC
14 November 2025
 

14 November 2025

MicroSalt Plc

 

("MicroSalt" or the "Company")

 

Trading Update

 

MicroSalt (AIM:SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, is pleased to provide the following trading update and continuing advancement of its B2B bulk business.

 

Unaudited sales for the 10 months ended 31 October 2025 total $1.66 million and the Board is confident of exceeding its original expectation of full year revenue of $2.0 million.

 

In its H1 2025 Trading Update on 18 August 2025, the Company announced that it had received increased North America volume projections from whom it describes as Customer 3, one of the world's largest food, soft drink and snack manufacturers. Whilst non-contractual, MicroSalt is confident in these volume projections which included a single new item, representing an addition to the Company's existing sales pipeline with Customer 3 and its divisions. The volume projections for this product (in North America only) indicate commencing rollout in Q2 2026 and resultant sales exceeding $5.0 million in 2026, expanding to $11.0 million in 2027. Whilst the Company continues to expect full rollout in mid-2026, it is pleased to announce it has received a first bulk purchase order that will ultimately be delivered to a specific end retailer of Customer 3 and that it expects to receive similar orders on a broadly monthly basis going forward.

 

Importantly, the depth and breadth of MicroSalt's relationships with Customer 3 continue to expand, with the signing of a non-binding term sheet outlining a proposed four-year Joint Development Agreement ("JDA") between Customer 3 and MicroSalt to facilitate the global joint development of new solutions for reduction of sodium content in food products while delivering familiar salty taste.

 

On 12 November 2025, the Company announced a new strategic relationship with Daiya Foods, a global leader in dairy-free and plant-based innovation. MicroSalt has received an initial order of $50k to begin production and its projected 2026 volume to approximately $500k.

 

Accordingly, the Company is now projecting 2026 sales to total $7.0 million based on in-hand volume estimations and its current customer base, rising to more than $15.0 million in 2027.

 

Rick Guiney, CEO of MicroSalt, commented:

 

"Our success in 2025 stems from focused strategic efforts to build a long lived, sustainable organisation that not only delivers healthier foods, but that also delivers top line revenue and investor returns. The projections for 2026, 2027 are based upon our existing volume commitments and as we scale, we expect enhanced efficiencies and additional product development to support continued success. 2025 serves as a foundational building block by providing impeccable reference sales that will solidify our position in the market going forward."

 

 

Enquiries:

 

MicroSalt plc

info@microsaltinc.com

Rick Guiney (CEO)

Zeus (Nominated Adviser and Broker)

+44 (0)20 3829 5000

David Foreman / James Edis (Investment Banking)

Gracechurch Group (Financial PR)

+44 (0)20 4582 3500

Heather Armstrong, Alexis Gore, Rebecca Scott

 

 

About MicroSalt

 

MicroSalt® is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt® delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Year to date through 2025, MicroSalt® has contributed to more than 634M servings made healthier.

 

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year. 

 

Operational since 2018, MicroSalt® has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.

 

MicroSalt® is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt® is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.

 

For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZMMMGDDGKZG
12
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
28th May 20267:07 amRNSFinal Results
28th Apr 20267:00 amRNS-RMicroSalt Launches MicroSalt Fibre
5th Mar 20267:00 amRNS-RNew UK customer
2nd Mar 20267:00 amRNS-RMicroSalt Reaches One Billion Servings Milestone
13th Feb 20267:00 amRNSGrant of options and PDMR dealings
27th Jan 20267:25 amRNSSigned Joint Development Agreement
12th Jan 20267:00 amRNSTrading Update
15th Dec 20252:17 pmRNSAdmission, Director Dealings and TVR
12th Dec 20252:30 pmRNSResult of Retail Offer
9th Dec 20254:35 pmRNSLaunch of Retail Offer
9th Dec 20252:40 pmRNSSubscription to raise £1.5 million
21st Nov 20253:38 pmRNSExercise of Stock Options and Total Voting Rights
14th Nov 20257:00 amRNSTrading Update
12th Nov 20257:00 amRNSNew Strategic Relationship with Daiya Foods
30th Sep 20257:00 amRNSUnaudited Half-yearly Report
1st Sep 20257:00 amRNSBoard changes
18th Aug 20257:00 amRNSH1 2025 Trading Update
11th Aug 20257:00 amRNSMissed related party transaction
6th Aug 20257:38 amRNSRelated Party Transaction
27th Jun 20253:48 pmRNSResult of AGM
6th Jun 202512:30 pmRNSHolding(s) in Company
2nd Jun 20257:01 amRNSNotice of Investor Presentation 9th June 2025
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
24th Apr 20257:00 amRNSQ1 2025 Business Update
24th Mar 20257:00 amRNS-RIFE London Innovation in Nutritious Foods
19th Mar 20257:00 amRNS-RFast Award 2025
25th Feb 20257:00 amRNS-RTechnology of the Year 2025 Award
14th Feb 20251:22 pmRNSNotification of Major Holdings
14th Feb 20251:06 pmRNSNotification of Major Holdings
7th Feb 20257:00 amRNSFurther Re Fundraising
5th Feb 20257:00 amRNSExercise of Stock Options and Total Voting Rights
3rd Feb 20257:00 amRNSOversubscribed Fundraising of £2.3Million
16th Jan 20257:00 amRNS-RFDA Nutrition information on packaged foods
6th Jan 20254:51 pmRNSResults of General Meeting
10th Dec 20247:00 amRNSShareholder Circular and Notice of General Meeting
30th Oct 20247:00 amRNSNew and Follow-on B2B Customer Orders
18th Oct 20247:00 amRNSResponse to Share Price Movement
27th Sep 20247:00 amRNSMaiden Interim Results
16th Sep 20247:00 amRNSMultiple Placements of Products and B2B Progress
2nd Aug 20243:02 pmRNSNotification of Major Holdings
30th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
16th Jul 20247:00 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
2nd Jul 20243:31 pmRNSExercise of Warrants and Total Voting Rights
21st Jun 20243:17 pmRNSResult of AGM
17th Jun 202411:22 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jun 20247:00 amRNSExercise Warrants Options and Total Voting Rights
30th May 20247:20 amRNSFinal Year end Results and Notice of AGM
24th May 20244:18 pmRNSExercise of Warrants
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.